Pathology of Peritoneal Metastases

Olivier Glehen • Aditi Bhatt Editors

Pathology of Peritoneal Metastases

The Unchartered Fields



Editors Olivier Glehen General and Oncologique Surgery Centre Hospitalier Lyon-Sud Lyon France

Aditi Bhatt Department of Surgical Oncology Zydus Hospital Ahmedabad India

ISBN 978-981-15-3772-1 ISBN 978-981-15-3773-8 (eBook) https://doi.org/10.1007/978-981-15-3773-8

© Springer Nature Singapore Pte Ltd. 2020

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore

Preface

This is a book on pathology of peritoneal metastases that has been edited and largely authored by surgeons which is unusual. Peritoneal surface oncology is a field that has always been at the cross roads—in the early years of evolution of surgical treatment, hyperthermia was being increasingly used to potentiate cancer therapy and thus was combined with the surgical treatment of peritoneal metastases, that is, cytoreductive surgery. The surgery itself had to prove its merit over systemic therapies and was burdened with proving the merit of another treatment that added to the morbidity. Similarly, disease biology was only partially understood and remains a major challenge for future progresses. While the prognostic factors were still being identified, and validated, oncology ushered into the era of genetics and molecular biology. And the gaps in understanding the pathophysiology of peritoneal metastases persisted. Pathological expertise has largely been directed at the diagnosis and classification of uncommon tumors.

During cytoreductive surgery that comprises of peritonectomy procedures and visceral resections, a large amount of tissue is submitted for histopathological evaluation. This remains a potential source of prognostic information regarding tumor biology. It provides a good opportunity to also study the patterns and pathways of peritoneal dissemination from various tumors.

In this book, we use these pathological findings to better explain the patterns and pathways of peritoneal cancer dissemination and their potential implications on clinical practice. We provide a rationale and recommendations for standardizing CRS procedures and evaluation of surgical specimens. In turn, we raise research question that can be addressed in future studies.

Some of the other aspects of pathological evaluation like pathological response to chemotherapy, diagnosis and classification of rare peritoneal tumors have also been covered in different chapters. Keeping in sync with the progress in molecular oncology, we look at the role of molecular oncology in the current and future management of peritoneal metastases.

We are grateful to all the contributors for lending their time and expertise to this book. We are also grateful to our pathology colleagues for their invaluable contribution to this work.

3 December 2019

Olivier Glehen Aditi Bhatt

Contents

1	Mechanisms of Peritoneal Metastasis Formation1Yutaka Yonemura, Haruaki Ishibashi, Akiyoshi Mizumoto, Kazuo Nishihara, Yang Liu, Satoshi Wakama, Syouzou Sako, Nobuyuki Takao, Masumi Ichinose, Shun-ichi Motoi, Keizou Taniguchi, Sachio Fushida, Yoshio Endou, and Masahiro Miura1
2	Extent of Peritoneal Resection for Peritoneal Metastases:Inferences from Pathophysiology27Aditi Bhatt and Olivier Glehen27
3	Therapeutic Rationale and Data Set for ReportingCytoreductive Surgery Specimens.47Aditi Bhatt, Nazim Benzerdjeb, Suniti Mishra, and Olivier Glehen47
4	Colorectal Peritoneal Metastases: CorrelatingHistopathological Findings and Disease Biology67Aditi Bhatt and Olivier Glehen67
5	Epithelial Serous Ovarian Cancer: Patterns of PeritonealDissemination and their Clinical Implications.89Aditi Bhatt, Loma Parikh, Suniti Mishra, and Olivier Glehen
6	Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination
7	The Pathological Spectrum of Mucinous AppendicealTumours and Pseudomyxoma Peritonei131Aditi Bhatt, Suniti Mishra, Loma Parikh, and Olivier Glehen
8	Genomics in Pseudomyxoma Peritonei
9	Peritoneal Regression Grading Score (PRGS) for TherapyResponse Assessment in Peritoneal MetastasisMiebke Solass

10	Rare Peritoneal Tumours: Histopathological Diagnosis
	and Patterns of Peritoneal Dissemination
	Suniti Mishra, Snita Sinukumar, Nutan Jumale, Loma Parikh,
	Aditi Bhatt, and Olivier Glehen

- 11
 Approach to a Patient with Peritoneal Metastases

 with Unknown Primary Site: Focus on Histopathological
 229

 Evaluation
 229

 Aditi Bhatt, Loma Parikh, Suniti Mishra, and Olivier Glehen
 229
- **12 Biomarkers in the Management of Peritoneal Metastases** 251 Ninad Katdare, Aditi Bhatt, and Olivier Glehen

About the Editors

Olivier Glehen is a world renowned expert in peritoneal surface oncology and a member of the executive committee of the peritoneal surface oncology group international (PSOGI). He is the head of the General and Oncologic Surgery Department at Centre Hospitalier Lyon Sud (Hospices Civils de Lyon) and at the Lyon Sud Charles Mérieux Medical Faculty. His centre is one of centres that have pioneered the surgical treatment of peritoneal metastases in the world. He is director of the Peritoneal Carcinomatosis Research Group from the EMR 3738 (Claude Bernard Lyon 1 University).

He has published extensively about peritoneal metastases. He is at the head of RENAPE (French Network on rare peritoneal tumours) and BIG-RENAPE groups (National Clinic-Biological Database on Digestive Peritoneal Carcinomatosis). He is associate editor of European Journal of Surgical Oncology, Journal of Surgical Oncology and Journal of Peritoneum. Professor Glehen is one of the directors of the Inter-University Diploma on Peritoneal Carcinomatosis in France and his centre is a reference centre for the European Society of Peritoneal Surface Oncology (ESPSO) certified fellowship in peritoneal surface oncology. His centre performs more than 200 HIPEC cvtoreductive surgery and (Hyperthermic Intraperitoneal Chemotherapy) procedures a year and is also one of the leading centers in the world that is developing PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy).

Aditi Bhatt is an Indian surgical oncologist specializing in the management of peritoneal surface malignancies with an experience of 10 years in the same. She is one of the founding members of the Society of peritoneal surface oncology, India, the Indian HIPEC registry and serves as the honorary secretary of the Asian Peritoneal Surface Malignancy Group.

She has published several scientific papers on the subject, edited two special issues of the Indian Journal of Surgical Oncology on the same and edited a book on peritoneal surface malignancies.